CEO leaning into the promise of AI for biotech? Not so fast, it can hurt firm value
Healthcare CEOs that “over-hype” coming innovations suddenly or inconsistently are punished by shareholders - unless they can follow it up with results well beyond industry averages.
Simple criteria for a biopharma to never lose licensing deals post-acquisition
Biotech R&D partnerships (and potential fees) get lost post-acquisition - learn how to screen for firms that will keep them
China’s trillion-dollar hydrogen market - how to predict industrial first movers
Chinese industrials with a 20%+ institutional shareholder makeup are more likely to explore hydrogen transition
The trick for using “green bonds” to access institutional equity
Issuing green bonds for sustainability projects can increase stock price and ownership amongst key institutional investors
Basing remote salary on geography? There may be a less contentious solution
Easy way to make high-burnout employees into low-turnover ones
Big Value in Big Data? Here's how to signal the market about it
![ESG investors be warned, look for these [counterintuitive] signs in your portfolio](https://images.squarespace-cdn.com/content/v1/64b968f77321602fb2f87390/1704515454530-QW0P5N09LLGA98HU5F3C/iStock-green+investing.jpeg)
ESG investors be warned, look for these [counterintuitive] signs in your portfolio
![The spin-off brain drain, when it is [and isn't] worth it](https://images.squarespace-cdn.com/content/v1/64b968f77321602fb2f87390/1704515547531-IHZAJP5HHVCQYXUB1E45/iStock-staff+redeployment.jpeg)